PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.72%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
7.72%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
12.50%
Net income growth under 50% of CRVO's 171.19%. Michael Burry would suspect the firm is falling well behind a key competitor.
15.94%
EPS growth under 50% of CRVO's 53.75%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
15.94%
Diluted EPS growth under 50% of CRVO's 63.90%. Michael Burry would worry about an eroding competitive position or excessive dilution.
4.10%
Share count expansion well above CRVO's 4.74%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
4.10%
Diluted share reduction more than 1.5x CRVO's 34.19%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-32.84%
Negative OCF growth while CRVO is at 19.61%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-32.79%
Negative FCF growth while CRVO is at 18.08%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48098.63%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-29341.33%
Negative 5Y OCF/share CAGR while CRVO is at 94.47%. Joel Greenblatt would question the firm’s operational model or cost structure.
-23.11%
Negative 3Y OCF/share CAGR while CRVO stands at 93.04%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-39968.68%
Negative 10Y net income/share CAGR while CRVO is at 1979.13%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-32.05%
Negative 5Y net income/share CAGR while CRVO is 100.79%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-188.96%
Negative 3Y CAGR while CRVO is 154.34%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
7755.72%
10Y equity/share CAGR above 1.5x CRVO's 306.53%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
2687.68%
5Y equity/share CAGR above 1.5x CRVO's 100.19%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-9.18%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.82%
We have a declining book value while CRVO shows 105.83%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Our R&D shrinks while CRVO invests at 17.07%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-14.34%
We cut SG&A while CRVO invests at 15.63%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.